|本期目录/Table of Contents|

[1]I.A.SUCHKOV,R.E.KALININ.Angiotensin-converting-enzyme Inhibitors in Treatment of Atherosclerotic Peripheral Arterial Disease[J].宁夏医科大学学报,2013,(07):733-737.
点击复制

Angiotensin-converting-enzyme Inhibitors in Treatment of Atherosclerotic Peripheral Arterial Disease(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2013年07期
页码:
733-737
栏目:
论著
出版日期:
2013-07-20

文章信息/Info

Title:
-
作者:
I.A.SUCHKOV R.E.KALININ
Ryazan State Medical University, Ryazan 390026, Russia
Author(s):
-
关键词:
neointimal hyperplasia endothelial dysfunction perindopril
Keywords:
-
分类号:
R541.4
DOI:
-
文献标志码:
A
摘要:
Objective To evaluate the treatment efficacy of perindopril in correcting endothelial dysfunction in patients with atherosclerotic peripheral arterial disease(PAD). Methods 85 patients with atherosclerotic PAD were divided into 3 groups and undergone endotheliotropic treatment with perindopril. The functional state of endothelium(FSE)was evaluated in all patients by checking the following biochemical parameters: nitric oxide(II)(NO), endothelin-1(E-1), C-reactive protein(CRP), superoxide dismutase(SOD), integral assessment of lipid peroxidation(LPO), glutathione peroxidase(GPx). Results Basal level of NO secretion in operated patients was the lowest. SOD level in operated patients increased by 102.7%, 143.24%, 164.86% and 175.67% directly after the operation as well as 1, 3 and 6 months following the surgery respectively, but E-1 level decreased by 82%, 70%, 78%, and 90%. The results of GPx level and LPO analysis confirmed favorable effects of perindopril on biochemical status in patients with atherosclerotic PAD. Conclusion Perindopril is effective in stimulating NO(II)secretion and correcting FSE. Perindopril may be used for prophylaxis of restenosis of reconstruction area following operative treatment in patients with atherosclerotic PAD.
Abstract:
-

参考文献/References:

[1] AV Pokrovsky.Clinical Angiology:Manual/Moscow[M].Publishing house Medicine,2004:1400.
[2] Kalinin RE,Shvalb PG,Kalinin RE.Antioxidant protection and functional state of endothelium in patients with atherosclerotic peripheral arterial disease before and after operative treatment[J].Surgery,2009,(1):53-55.
[3] G Pedersen.Improved patency and reduced intimal hyperplasia in PTFE grafts with luminal immobilized heparin compared with standard PTFE grafts at six months in a sheep model[J].J Cardiovasc Surg(Torino),2010,51(3):443-448.
[4] Brune B,Sandau K,von Knethen A.Apoptotic cell death and nitric oxide:activating and antagonistic transducing pathways[J].Biochemistry(Mosc),1998,63(7):817-825.
[5] Stoclet JC.Muller B.Andriantsitohaina R.Kleschyov A.Overproduction of nitric oxide in pathophysiology of blood vessels[J].Biochemistry(Mosc),1998,63(7):826-832.
[6] T Shirasawa.Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury[J].J Atheroscler Thromb,2009,16(6):772-781.
[7] Paltsev MA.Intercellular interactions.-2nd edition.Moscow[M].Publishing house Medicine,2003:288.
[8] CG Pearce.Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia [J].Free Radic Biol Med,2008,44(1):73-81.
[9] T Shirasawa.Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury[J].J Atheroscler Thromb,2009,16(6):772-781.

相似文献/References:

备注/Memo

备注/Memo:
收稿日期:2013-02-09
更新日期/Last Update: 2013-07-20